GLP-1
US$ 22.74
gip receptor tirzepatide Understand GLP-1/GIP Dual Agonist and Its Effect on Current Weight Loss Therapy Bumps and humps in the
Description
This finding is consistent with the results of previous analyses, indicating high confidence in the results
August 4, 2022
An interesting paper was just published looking at the way that drugs like Ozempic seem to reduce alcohol and drug use in the real world
[DOI] [PMC free article] [PubMed] [Google Scholar] 101.Khom S, et al
For the primary endpoint, the relative risk reduction in the mITT1 analysis population for PAXLOVID compared to placebo was 86% (95% CI: 72%, 93%)
however, if oral semaglutide were used, additional spacing would be necessary
